Annals of hepatology · 2026
Secondary prophylaxis of SBP in cirrhosis: trimethoprim-sulfamethoxazole vs. ciprofloxacin in a propensity-matched cohort.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Osman Mohamad Mahdi, Sims Omar T, Chiang Dian J
Аннотация
INTRODUCTION AND OBJECTIVES: Spontaneous bacterial peritonitis (SBP1) is a common complication of cirrhosis. In the United States, inconsistent norfloxacin availability has shifted secondary SBP prophylaxis toward ciprofloxacin or trimethoprim-sulfamethoxazole (TMP-SMX2), but these agents have not been robustly compared head-to-head. We compared clinical outcomes among patients receiving TMP-SMX versus ciprofloxacin for secondary SBP prophylaxis.
MATERIALS AND METHODS: We conducted a multicenter retrospective cohort study using the TriNetX de-identified electronic health record network. Adults with cirrhosis (ICD-10 K74.6) and SBP (ICD-10 K65.2) from January 2013 to July 2021 were included. Index date was the first prescription for TMP-SMX (RxNorm 10,829/10180) or ciprofloxacin (RxNorm 2551), with follow-up through July 11, 2024. Exclusions included prior exposure to the alternative agent, liver transplant, or end-stage renal disease. We performed 1:1 greedy nearest-neighbor propensity score matching (caliper 0.1) on demographics, comorbidities, and hepatic/renal laboratory variables. Primary outcomes were SBP recurrence and all-cause mortality; secondary outcomes included all-cause hospitalization, variceal bleeding, hepatic encephalopathy, and ascites. Cox proportional hazards models estimated hazard ratios (HRs).
RESULTS: Among 31,011 patients (TMP-SMX 11,166; ciprofloxacin 19,845), 11,140 well-balanced matched pairs were analyzed. TMP-SMX was associated with lower SBP recurrence (HR 0.75, 95% CI 0.72-0.79) and all-cause mortality (HR 0.84, 95% CI 0.80-0.87; both p < 0.0001). TMP-SMX also reduced risks of variceal bleeding (HR 0.81), hepatic encephalopathy (HR 0.79), and ascites (HR 0.86), while hospitalization was not significantly different.
CONCLUSIONS: TMP-SMX was associated with significantly lower SBP recurrence and mortality than ciprofloxacin, supporting TMP-SMX as a potentially more effective secondary prophylaxis option pending randomized confirmation.
MATERIALS AND METHODS: We conducted a multicenter retrospective cohort study using the TriNetX de-identified electronic health record network. Adults with cirrhosis (ICD-10 K74.6) and SBP (ICD-10 K65.2) from January 2013 to July 2021 were included. Index date was the first prescription for TMP-SMX (RxNorm 10,829/10180) or ciprofloxacin (RxNorm 2551), with follow-up through July 11, 2024. Exclusions included prior exposure to the alternative agent, liver transplant, or end-stage renal disease. We performed 1:1 greedy nearest-neighbor propensity score matching (caliper 0.1) on demographics, comorbidities, and hepatic/renal laboratory variables. Primary outcomes were SBP recurrence and all-cause mortality; secondary outcomes included all-cause hospitalization, variceal bleeding, hepatic encephalopathy, and ascites. Cox proportional hazards models estimated hazard ratios (HRs).
RESULTS: Among 31,011 patients (TMP-SMX 11,166; ciprofloxacin 19,845), 11,140 well-balanced matched pairs were analyzed. TMP-SMX was associated with lower SBP recurrence (HR 0.75, 95% CI 0.72-0.79) and all-cause mortality (HR 0.84, 95% CI 0.80-0.87; both p < 0.0001). TMP-SMX also reduced risks of variceal bleeding (HR 0.81), hepatic encephalopathy (HR 0.79), and ascites (HR 0.86), while hospitalization was not significantly different.
CONCLUSIONS: TMP-SMX was associated with significantly lower SBP recurrence and mortality than ciprofloxacin, supporting TMP-SMX as a potentially more effective secondary prophylaxis option pending randomized confirmation.